FIGURE 2.

The measurements of metabolites in Data set 2. Glycerophosphocholine (A), aspartic acid (B), hydroxypalmitic acid (C), and choline (D), were increased; and hexanoylcarnitine AcCa (6:0) (E), 4‐decenoylcarnitine AcCa (10:1) (F), tetradecadiencarnitine AcCa (14:2) (G), piperine (H), decanoylcarnitine AcCa (10:0) (I), L‐acetylcarnitine (J), and serotonin (K) levels were decreased in AD patients. Abbreviations: AD, Alzheimer's disease; FC, fold‐change. All P’s < .001 for each metabolite compared between AD and control